|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-8-3
|
|
pubmed:abstractText |
Circulating lymphocytes of obese individuals with and without type 2 diabetes have derangements of pyruvate dehydrogenase (PDH) that are described as reflecting a disorder underlying systemic insulin resistance, namely basal activity below normal and, in vitro, unresponsiveness to insulin at 33 pmol/l and activation at 330 pmol/l instead of activation and inhibition as in controls.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0307-0565
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
735-41
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10878680-Adult,
pubmed-meshheading:10878680-Blood Glucose,
pubmed-meshheading:10878680-Body Mass Index,
pubmed-meshheading:10878680-Dexfenfluramine,
pubmed-meshheading:10878680-Diabetes Mellitus,
pubmed-meshheading:10878680-Enzyme Activation,
pubmed-meshheading:10878680-Female,
pubmed-meshheading:10878680-Humans,
pubmed-meshheading:10878680-Insulin,
pubmed-meshheading:10878680-Insulin Resistance,
pubmed-meshheading:10878680-Lymphocytes,
pubmed-meshheading:10878680-Male,
pubmed-meshheading:10878680-Middle Aged,
pubmed-meshheading:10878680-Obesity,
pubmed-meshheading:10878680-Placebos,
pubmed-meshheading:10878680-Pyruvate Dehydrogenase Complex,
pubmed-meshheading:10878680-Weight Loss
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
In obese individuals dexfenfluramine corrects molecular derangements reflecting insulin resistance.
|
|
pubmed:affiliation |
Department of Experimental Medicine and Oncology, Section of Biochemistry, University of Turin, Turin, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
